Sandy Bassin, MD Medical Reviewer Sandy Bassin, MD, is an endocrinology fellow at Mount Sinai in New York City
The sixth is cardiometabolic indication expansion
Take Action Today Every day matters: Evidence may be lost over time Statutes of limitations are approaching for some patients Early filing may position you better in the MDL Your health and financial recovery are at stake You have nothing to lose and potentially much to gain by finding out if you have a case
[20] [21] Seek urgent medical advice if you are already taking a GLP-1 medication and experience: Severe, persistent abdominal pain (possible pancreatitis) A new lump in your neck or changes in your voice Symptoms of severe hypoglycaemia (if taking other diabetes medications) Signs of thyroid dysfunction despite stable levothyroxine therapy Persistent vomiting leading to dehydration or inability to take oral medications Severe right upper abdominal pain, fever or jaundice (possible gallbladder disease) Open communication with your healthcare team ensures that treatment decisions are individualised, evidence-based, and aligned with your health priorities
The trial currently has almost 10,000 patients enrolled and is expected to assess a composite MACE endpoint consisting of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D as is expected to readout in July 2024 (NCT03574597)
